CLINICAL TRIAL LEADERSHIP
Matrix Biomed, Inc. strives to engage the top physicians, researchers, and medical professionals during their clinical trial site selection process. This involves evaluating the expertise and capabilities of all potential medical monitors and principle investigators to ensure the highest level of safety, accuracy, and compliance in conducting clinical trials.
Zeljko Vujaskovic, M.D., Ph.D
Dr. Vujaskovic is the medical monitor for the clinical trials with Matrix Biomed, Inc. who provides invaluable insight and review of clinical procedures and standards. He is a physician/scientist and professor who heads the Division of Translational Radiation Sciences in the Department of Radiation Oncology at the University of Maryland School of Medicine (UMSOM) in Baltimore. For more than 30 years, his career has been defined by transdisciplinary research that bridges the gap between basic science and clinical research to ultimately improve outcomes and long-term quality of life among cancer patients. Dr. Vujaskovic has published more than 150 articles and book chapters on radiation therapy, radiation injury, and hyperthermia topics. He has directed national and international research collaborations and is an active participant in cooperative group trials. In 2016 he was honored with the Society for Thermal Medicine’s J. Eugene Robinson Award, given each year to an investigator who has made outstanding contributions to hyperthermic oncology.
Katherine Tkaczuk, M.D.
Dr. Tkaczuk is the principal investigator on MBI-08-01 and is integral in the design and development of MBI-08-01. Her research interests are focused on clinical drug development in in breast cancer (BC). From 1992 to present, she has been involved in 100+ phase 1-3 clinical trials and has served as the institutional principal investigator (PI) on the majority of the University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC) specific clinical trials. As the Director of UMGCCC Breast Evaluation and Treatment Program (BETP), a multidisciplinary program with commitment to comprehensive, multidisciplinary breast cancer care, she oversees the clinical and research aspects of the program.The UMGCCC clinical breast program continues to work in the area of clinical drug development with the focus on hormone resistance, role of microtentacles in breast cancer metastasis, the significance of brown adipose tissue in pathogenesis and progression of breast cancer, and the GP-88 circulating marker and its significance in patients with breast cancer and in screening for breast
Robert Malyapa, M.D., Ph.D
Dr. Malyapa is a nationally and internationally recognized proton therapy physician. With over 70 peer-reviewed publications, 2 book chapters, and 80 national and international presentations, Dr. Malyapa brings a wealth of expertise as a principal investigator for Matrix Biomed, Inc.’s current clinical trial. Dr. Malyapa has over a decade of experience treating cancers of the brain, base of skull, head and neck, spine and sarcoma. He is a Professor of Radiation Oncology of the University of Maryland School of Medicine.